

D.L. Acidophilus + Pectin

Beneficial flora for healthy intestinal function

DESCRIPTION

D.L. Acidophilus + Pectin capsules, provided by Douglas Laboratories®, contain a synergistic blend of the beneficial microorganisms *Lactobacillus acidophilus* and *Lactobacillus bulgaricus* for gastrointestinal health.

FUNCTIONS

Oral supplements of live, beneficial intestinal microorganisms for nutritional health and well-being are known as probiotics. Probiotic dietary acidophilus colonize the intestinal tract, depending on the specific bacterium-to-host affinity. Bacteria are continually in competition for colonization space. The original bacterial colonies have an advantage over transient bacteria. Nevertheless, the composition of the intestinal microflora is dynamic and constantly changing.

If harmful microorganisms proliferate, the equilibrium is disturbed, and it becomes difficult even for indigenous bacteria to maintain their necessary territory to colonize the intestine. Antibiotics tend to kill off both beneficial and harmful bacteria, and thus may also disturb the normal, healthy balance of intestinal microorganisms.

When potent probiotic supplements, such as D.L. Acidophilus + Pectin, are supplied regularly, chances are greatly increased for establishing and maintaining a healthy population of beneficial intestinal microorganisms. Once established, a normal intestinal microflora rich in lactobacilli creates acidic conditions that are unfavorable for the settlement of pathogenic microorganisms.

INDICATIONS

D.L. Acidophilus + Pectin capsules may be a useful dietary supplement for those who wish to support their intestinal microflora with meaningful amounts of beneficial microorganisms.

FORMULA (#7903)

1 capsule contains:

Lactobacillus Acidophilus and *Lactobacillus bulgaricus* Complex 550 Million CFU
Citrus Pectin 100 mg

SUGGESTED USE

Adults take 1-2 capsules, 2-4 times daily or as directed by your health care professional

SIDE EFFECTS

No adverse side effects reported

STORAGE

Store in a cool, dry place, away from direct light. Keep out of reach of children.

REFERENCES

- Cebra JJ. Influences of microbiota on intestinal immune system development. *Am J Clin Nutr* 1999;69:1046S-1051S.
- Collins MD, Gibson GR. Probiotics, prebiotics, and synbiotics: approaches for modulating the microbial ecology of the gut. *Am J Clin Nutr* 1999;69:1052S-1057S.
- Donnet-Hughes A, Rochat F, Serrant P, Aeschlimann JM, Schiffrin EJ. Modulation of nonspecific mechanisms of defense by lactic acid bacteria: effective dose. *J Dairy Sci* 1999;82:863-9.
- Elmer GW, Surawicz CM, McFarland LV. Biotherapeutic agents. A neglected modality for the treatment and prevention of selected intestinal and vaginal infections [see comments]. *Jama* 1996;275:870-6.
- Gibson GR. Dietary modulation of the human gut microflora using prebiotics. *Br J Nutr* 1998;80:S209-12.
- Goldin BR. Health benefits of probiotics. *Br J Nutr* 1998;80:S203-7.
- Jacobsen CN, Rosenfeldt Nielsen V, Hayford AE, Moller PL, Michaelsen KF, Paerregaard A, Sandstrom B, Tvede M, Jakobsen M. Screening of probiotic activities of forty-seven strains of *Lactobacillus* spp. by *In vitro* techniques and evaluation of the colonization ability of five selected strains in humans [In Process Citation]. *Appl Environ Microbiol* 1999;65:4949-56.
- Kirjavainen PV, Ouwehand AC, Isolauri E, Salminen SJ. The ability of probiotic bacteria to bind to human intestinal mucus. *FEMS Microbiol Lett* 1998;167:185-9.
- Pessi T, Sutas Y, Saxelin M, Kallioinen H, Isolauri E. Antiproliferative effects of homogenates derived from five strains of candidate probiotic bacteria [In Process Citation]. *Appl Environ Microbiol* 1999;65:4725-8.
- Tejada-Simon MV, Lee JH, Ustunol Z, Pestka JJ. Ingestion of yogurt containing *Lactobacillus acidophilus* and *Bifidobacterium* to potentiate immunoglobulin A responses to cholera toxin in mice. *J Dairy Sci* 1999;82:649-60.
- Venturi A, Gionchetti P, Rizzello F, Johansson R, Zucconi E, Brigidi P, Matteuzzi D, Campieri M. Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. *Aliment Pharmacol Ther* 1999;13:1103-8.
- Wang X, Ma G, Zheng B, Tian H. [Effects of SL-probiotic preparation on the body weight and phagocytosis of white mice]. *Wei Sheng Wu Hsueh Pao* 1995; 35:455-9.

(continued on reverse)

**These statements have not been evaluated by the Food and Drug Administration.
This product is not intended to diagnose, treat, cure, or prevent any disease.**

**Manufactured by
Douglas Laboratories
600 Boyce Road
Pittsburgh, PA 15205
800-245-4440**